Regeneron Pharmaceuticals

REGN7508 (catalytic domain) and REGN9933 (A2 domain) show robust antithrombotic effects with minimal bleeding risk in Phase 2 trials post-knee replacement. Both antibodies demonstrated non-inferiority to current standards of care, with REGN7508 showing superiority to enoxaparin. No major bleeding incidents were reported. A Phase 3 program is planned for 2025.

Regeneron announced positive Phase 2 results for Factor XI antibodies REGN7508 and REGN9933, showing robust antithrombotic effects with no clinically relevant bleeding. REGN7508 was superior to enoxaparin and non-inferior to apixaban, while REGN9933 was non-inferior to enoxaparin. Plans to initiate Phase 3 trials in 2025.

Resonance Health acquired TrialsWest for A$8M, expanding into clinical trial operations. Outsourcing clinical trials enhances efficiency, cost-effectiveness, and regulatory compliance, benefiting companies by optimizing resources and focusing on core activities.

Resonance Health acquired TrialsWest for A$8M, expanding into clinical trials. The global Clinical Trial Outsourcing market was valued at USD 52.39B in 2023 and is projected to reach USD 111.01B by 2032, with a CAGR of 8.7%. Outsourcing offers cost-effectiveness, faster timelines, and regulatory compliance, but faces challenges like rising costs and undisclosed expenses.

The 'Macular Edema - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of global clinical trials on Macular Edema, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, and provides enrollment trends and recent news.

Bayer's QUASAR study showed aflibercept 8 mg, given every 8 weeks after initial monthly doses, achieved non-inferior visual acuity gains vs. Eylea 2 mg every 4 weeks in RVO patients. Aflibercept 8 mg demonstrated sustained disease control, rapid fluid reduction, and fewer injections with similar efficacy and safety. It's approved in over 50 countries for nAMD and DME, offering up to 5-month treatment intervals.

AI's integration with CRISPR accelerates gene-editing tool discovery, enhances precision, and improves delivery methods. Companies like Mammoth Biosciences, Profluent, and Beam Therapeutics lead in AI-CRISPR synergy, advancing diagnostics, therapeutics, and base editing. AI and CRISPR's future spans medicine, agriculture, and climate change, with potential applications in creating methane-free cows and revolutionizing drug discovery.

Eylea HD met primary endpoint in phase 3 QUASAR trial, improving vision with extended dosing intervals in patients with macular edema following retinal vein occlusion. Both Eylea HD groups achieved noninferior visual acuity gains compared to Eylea 2 mg. Regeneron plans to submit a supplementary biologics license application to the FDA in Q1 2025.

The MET targeting therapies market is poised for significant growth by 2034 due to rising cancer diagnoses, increased awareness, and numerous therapies in clinical trials. Key players include AstraZeneca, AbbVie, and Regeneron, with therapies like ORPATHYS and Telisotuzumab Vedotin in development. Regulatory approvals and precision medicine advancements are driving market dynamics, though challenges like pricing and reimbursement persist.

Regeneron's phase 3 QUASAR trial of EYLEA HD met primary endpoint, showing improved vision with fewer injections for retinal vein occlusion patients compared to EYLEA. EYLEA HD's safety profile was similar to EYLEA, and Regeneron plans to submit data to FDA in Q1 2025.